chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Revaccination with different COVID-19 vaccine; Interchange of vaccine products; ALMOST KILLED/A LONG LIST OF SIDE EFFECT; LITTLE HEAT AT THE SITE OF INJECTION; LOW GRADE FEVER; FATIGUE REOCCURENCE; This spontaneous case was reported by a consumer and describes the occurrence of IMMUNISATION REACTION (ALMOST KILLED/A LONG LIST OF SIDE EFFECT), VACCINATION SITE WARMTH (LITTLE HEAT AT THE SITE OF INJECTION), PYREXIA (LOW GRADE FEVER), FATIGUE (FATIGUE REOCCURENCE) and COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) for COVID-19 prophylaxis.    Previously administered products included for Prophylactic vaccination: INFLUENZA VACCINE and INFLUENZA VACCINE. Past adverse reactions to the above products included Fatigue with INFLUENZA VACCINE; and Injection site warmth with INFLUENZA VACCINE. Concurrent medical conditions included Abstains from alcohol, Non-smoker, Fibromyalgia, Anxiety disorder, Heartburn (Occasional), Difficulty sleeping, Chronic fatigue syndrome and Drug allergy. Concomitant products included ALPRAZOLAM (XANAX) and NAPROXEN (MOTRIN [NAPROXEN]) for Anxiety disorder.   On 19-Mar-2021, the patient received first dose of COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) (unknown route) 1 dosage form. On 29-Oct-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced IMMUNISATION REACTION (ALMOST KILLED/A LONG LIST OF SIDE EFFECT), VACCINATION SITE WARMTH (LITTLE HEAT AT THE SITE OF INJECTION), PYREXIA (LOW GRADE FEVER) and FATIGUE (FATIGUE REOCCURENCE). On 29-Oct-2021, the patient experienced COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). In 2021, PYREXIA (LOW GRADE FEVER) had resolved. At the time of the report, IMMUNISATION REACTION (ALMOST KILLED/A LONG LIST OF SIDE EFFECT), VACCINATION SITE WARMTH (LITTLE HEAT AT THE SITE OF INJECTION), FATIGUE (FATIGUE REOCCURENCE), COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) outcome was unknown.            The patient had no COVID infections after vaccination. Patient reported that adverse events were minor with no diarrhea and no vomiting.  Treatment medications were not reported.
swollen rt lower lid, chest tightness, anxiety;recv 1 dose of Epi & given DPH capsules;
Erythema, swelling; onset sometime between 4/5 - 4/15.
"Measles like rash" tiny red raised rash on face, scalp, trunk, extremities itchy, no fever.
Bell's palsy of right face - slight symptoms occurring 2 days after vaccination and worsened until noticed and taken to local ED 5 days after vaccination.
Swollen Lymphnode; Missed period; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a patient and describes the occurrence of LYMPHADENOPATHY (Swollen Lymphnode) and MENSTRUATION IRREGULAR (Missed period) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date, the patient experienced LYMPHADENOPATHY (Swollen Lymphnode) and MENSTRUATION IRREGULAR (Missed period). At the time of the report, LYMPHADENOPATHY (Swollen Lymphnode) and MENSTRUATION IRREGULAR (Missed period) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment medications were not provided.  Concomitant medications was not given.
Joint pain; Low grade fever; Rash at injection site; Sore at injection site; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of ARTHRALGIA (Joint pain), PYREXIA (Low grade fever), VACCINATION SITE RASH (Rash at injection site) and VACCINATION SITE PAIN (Sore at injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 03-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Mar-2021, the patient experienced ARTHRALGIA (Joint pain), PYREXIA (Low grade fever), VACCINATION SITE RASH (Rash at injection site) and VACCINATION SITE PAIN (Sore at injection site). At the time of the report, ARTHRALGIA (Joint pain), PYREXIA (Low grade fever), VACCINATION SITE RASH (Rash at injection site) and VACCINATION SITE PAIN (Sore at injection site) outcome was unknown. Not Provided          For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was not applicable. No concomitant and treatment medications were reported.
Patient states that she started having pain a few hours after the vaccine. She states she has had flu shots previously without the same type of pain. She states that her arm gets very stiff at night. She ices her arm in the morning and take Tylenol and ibuprofen to get through the day.
By nightfall on the day of my second dose, I was extremely jaundiced. The following morning, my urine was darker than it has ever been - a dark amber/brown color. These are symptoms that I do experience routinely as someone with CAD. Hemolysis causes these same symptoms, but it seems the vaccine accelerated the hemolysis for some reason. Perhaps it activated complement. Regardless, this event did not last beyond the weekend, and has not been an issue since. I just thought it should be recorded as an adverse event.
Rash; itchiness; Radiating pain up and down leg;  A spontaneous report was received from a Consumer concerning a 82-years-old  patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events rash, itchiness, radiating pain up and down leg.  The patient's medical history was not provided. Concomitant medications reported were Blood Pressure Medication for drug use for unknown indication.  On 2 Feb 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot/batch: OO7M2OA) intramuscularly for prophylaxis of COVID-19 infection.   Rash, Itchiness, Radiating pain up and down leg.  Treatment details included Put cream on rash, Ibuprofen  Action taken with mRNA-1273 in response to the events was not reported.   On an unknown date the outcome of events, rash, On an unknown date the outcome of events, itchiness, On an unknown date the outcome of events, radiating pain up and down leg was not reported.
ABOUT 20 MINUTES AFTER VACCINATION, MY HEART WAS RACING . I WASN'T UNCOMFORTABLE, JUST AWARE OF IT...THIS CONTINUED UNTIL ABOUT 7PM WHEN I WENT TO BED...MY ARM STARTED TO ITCH AND SWELL ABOUT 3 HRS AFTER THE VACCINATION...AT FIRST IT WAS A BUMP ABOUT THE SIZE OF A MOSQUITO BITE. OVER TIME IT BECAME BIGGER...BY THE NEXT MORNING, 12/21 IT WAS THE SIZE OF A SILVER DOLLAR AND IT WAS A HARD LUMP THAT PROTRUDED ABOUT1/2 IN FROM MY ARM..IT BECAME BIGGER FOR THE NEXT WEEK OR SO ABOUT THE SIZE OF A GOLF BALL...
Muscle pain, joints pain in my hands and toes; Hands are like numb and they are getting like lazy and I can't touch paper; like shaking together; Muscle pain, joints pain in my hands and toes; Muscle pain, joints pain in my hands and toes; Hands are like numb and they are getting like lazy and I can't touch paper; Toes are not moving like they use to; This is a spontaneous report from a contactable consumer or other non-Health Care Professional. This 30-year-old female consumer reported for herself that she received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number: EW0172 and Expiry date: Aug2021), via an unspecified route of administration, administered in Left arm on 26Apr2021 (at the age of 32-years-old) as DOSE NUMBER UNKNOWN, SINGLE for covid-19 immunization. The patient medical history was not reported.The patient's concomitant medications were not reported. On an unspecified date, the patient stated, "I called because I had side effects from this vaccine. Now I am having side effects that I never had before and the side effect that I had muscle pain, joints pain in my hands and toes, my hands are like numb and they were getting like lazy and I could not touch paper, now its my toes, my toe I am not moving, I got muscle pain and numbness and they were like shaking together, toes were not moving like they use to and I had muscle pain in my arm that I got the shot on 26th April, I had minor complications. Consumer further stated that I  still in pain right now. The patient underwent to emergency room and they gave Ibuprofen 600 mg tablet. The outcome of event was unknown.
Patient had a swollen, erythematous, slightly indurated and warm to the touch right thigh. (Almost complete anterior aspect of thigh was involved.)
Patient was given Pfizer Covid vaccine as booster dose in error.  Patient's first and second covid vaccine dose was Moderna.
Rash on waistline right side of body.  Rash is getting better as of 12 hours later.  Patient reports feeling achy and had chills this morning at onset of rash.
Pt had exposure to COVID on 1/14/22, started to have mild symptoms 1/15. She was fully vaccinated and boosted. Mild SOB/hypoxia (87% on room air).   No N/V, diarrhea, chills, fatigue, muscle aches. She was recently diagnosed with pulmonary fibrosis. Has been admitted before with hypoxia from ILD exacerbation, treated with steroids. She reports that back then she felt much worse when she presented to the ER; seems that her walking sats were in the 70s at the time. She reports taking advair and albuterol BID scheduled. She was exposed to her niece who had exposure to someone with COVID so she went to the tent today for testing and was referred here after her oxygen measurement was 88% and was admitted for hypoxia
Patient received first dose on 3/11/2021 and second dose on 3/16/2022.  First booster provided on 5/31/2022 which was too early based upon current FDA recommendations for time separation between initial series and booster dose for Moderna.  Patient is not considered immunocompromised.
2 areas of accidential implantation - day 4 of vaccine 1-right jugular area 2-left scapula c/o lymphadenopathy, low grade fever, soreness at sites.
Headache Sedation, Myalgia, Fever, CHILLS Narrative:
Pt experienced the sensation of having a "lump" in her throat, symptoms resolved on their own without treatment shortly after the symptoms developed. The patient denied difficulty breathing, wheezing, chest pain/tightness. Pt denied any swelling  to the throat, tongues, eyes, lips or difficulty breathing.
Lump above from collarbone and swollen; Lump above from collarbone and swollen; This is a spontaneous report from a non-contactable consumer, the patient. A 32-year-old female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 05Apr2021 at 16:30 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 07Apr2021, two days after vaccination, the patient got a lump above from her collarbone and swollen. The events resulted in doctor or other healthcare professional office/clinic visit. It was unknown whether any therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events lump above from collarbone and swollen was not resolved at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
swelling of the arm; back side on the right part of the head goes numb; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (swelling of the arm) and HYPOAESTHESIA (back side on the right part of the head goes numb) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In November 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Dec-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-Dec-2021, the patient experienced PERIPHERAL SWELLING (swelling of the arm) and HYPOAESTHESIA (back side on the right part of the head goes numb). At the time of the report, PERIPHERAL SWELLING (swelling of the arm) and HYPOAESTHESIA (back side on the right part of the head goes numb) outcome was unknown.            No concomitant medications were reported. No treatment details were reported. Patent reported no allergies or medications. Patient had the event few hours after the second dose on 3 Dec 2021.   This case was linked to MOD-2021-405014 (Patient Link).
Ill after second dose.  Then all kinds of symptoms started happening.  Had ocular migraines, headaches,  fever, raised veins in temples, and more.  Was diagnosed with Giant Cell Arteritis  around October 20,2021.
Swollen lymph node near left clavicle, tender and painful to the touch.  Lessening but still present at 1 week post vaccine.
Body aches, fever, fatigue, swollen lymph nodes, soreness red and inflamed at injection site. Anaphylaxis later that night and next day
6 days post injection small hives began at injection sight. 7 days post injection the area became inflamed and hot to the touch.  I spoke with my pcp and it was decided we would continue to monitor the site.
Patient (68 year old male) received a flu shot on 10/10/07.   He died that night in his sleep of a massive heart attack, presumably in the early morning hours of 10/11/07.   Although previously diagnosed with mild artherosclerosis, he had never had a prior heart attack.   He had just visited his doctor the previous day and been given a clean bill of health.  5/6/09 Autopsy report states COD as artherosclerotic & hypertensive-type cardiovascular disease w/obesity as contributing condition.  Manner of death natural.  Report also states 40-50% stenosis of LAD by calcified atherosclerotic plaque; atherosclerosis of aorta; cardiomegaly; obesity, BMI 34; hx of hypercholesterolemia; mild pulmonary edema/congestion; prostatic nodular hyperplasia; hx of seizure disorder.
01/12/2022:  63-year-old female with a history of rheumatoid arthritis and lupus presented to the emergency room for altered mental status.  Patient was found unresponsive by her husband. Patient was seen and evaluated by me for altered mental status and unresponsiveness.  Per EMS, patient had thready pulses and constricted pupils.  The patient was given Narcan. -Plan 1: -Acute metabolic toxic encephalopath-Urine drug screen positive for cocaine Concern for aspiration pneumonia, viral COVID-19 pneumonia positive. Acute hypoxic hypercapnic respiratory failure, intubated
Pt reports pain and swelling began approximately 5 days after receiving influenza vaccine. Pt did have other multiple ailments. R delt 15x10 cm erythema heat. Front pains wrist and knee
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 64-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 18Oct2022 at 15:00 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 63 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "hypothyroid" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Feb2023, outcome "not recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive, notes: COVID 19 Treatment; (Feb2023) Negative, notes: Tested negative for two days; (Feb2023) Negative, notes: Tested negative for two days; (Feb2023) Positive, notes: Re-infected 4 days after completion of paxlovid. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: The patient was treated with paxlovid, started on 14Feb2023 and stopped on 19Feb2023. No known allergies.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Initial report was received from a health care professional on 03 January 2011 via a search of the literature. A 64-year-old female patient developed neurologic complications after she had received INFLUENZA (manufacturer unknown, lot number and date of administration not reported). Eighteen days after vaccination, the patient exhibited paraplegia and was diagnosed with acute idiopathic demyelinating polyradiculopathy (Guillain-Barre Syndrome). She received intravenous gammaglobulin therapy as corrective treatment with poor response. Outcome was not reported. The reporter for this case is the same as for case number 2011-00041. Documents held by sender: None
Patient reported sore arm 5 days after vaccine. Told patient to see if MD it does not get better or gets worse. pain did not get better patient saw MD and diagnosed with infection.
This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a 84-year-old female patient who received SHINGRIX (batch number 9YD45, expiry date unknown) for prophylaxis. On 11th September 2018, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. On 24th September 2018, 13 days after receiving SHINGRIX, the patient experienced shingles. On an unknown date, the outcome of the shingles was recovered/resolved. It was unknown if the reporter considered the shingles to be related to SHINGRIX. Additional information received as follows: The patient had no history of shingles. The pharmacist reported that one of his patient developed shingles. The patient lived in the patient's assistant living facility. On 24th September 2018, he was informed about the patient developing shingles.
Red dots on both hands; rash; This spontaneous case was reported by a consumer and describes the occurrence of RASH ERYTHEMATOUS (Red dots on both hands) and RASH (rash) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     No Medical History information was reported.  On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.   On 11-Feb-2021, the patient experienced RASH ERYTHEMATOUS (Red dots on both hands) and RASH (rash). At the time of the report, RASH ERYTHEMATOUS (Red dots on both hands) and RASH (rash) outcome was unknown. Unknown    The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   Concomitant product use was not provided by the reporter. No treatment information was provided.
NO ADVERSE EFFECT OCCURRED; PATIENT WAS GIVEN A SECOND BOOSTER SHOT ON 11/29/21.  HER FIRST BOOSTER WAS GIVEN ON 10/14/21.  THERE WAS MISCOMMUNICATION BETWEEN THE FACILITY AND PHARMACISTS WHO WENT BY TO DO VACCINES.  THE FACILITY BELIEVED SHE HAD NOT RECEIVED A BOOSTER ON 10/14/21 AND THE PHARMACIST WHO WENT ON 11/29/21 FELT CONFIDENT THAT SHE HAD NOT AND FAILED TO CHECK DATABASE TO CONFIRM.  PATIENT HAS RECEIVED A TOTAL OF 4 DOSES.  PATIENT HAS HAD ZERO REACTIONS FROM ANY OF THE DOSES.
I had a runny nose, and sore throat for a few days. I did a COVID home test on 2/6/22 that came back positive. I was given Paxlovid to take for 5 days. My symptoms lasted for about a week.
Patient was here to get 2nd dose Moderna Covid vaccine. Patient was given Pfizer vaccine in error.
Patient came in on 8-12-21 for 2nd dose of Pfizer, upon checking CAIRs noticed patient already received Janssen on 3-19-2021 at another facility. Patient failed to disclose that she had received Janssen when asked verbally & on her consent form & was given her 1st dose of Pfizer on 7-15-2021. No adverse reactions were reported
patches in glutes; itch; This spontaneous case was reported by a consumer and describes the occurrence of RASH MACULAR (patches in glutes) and PRURITUS (itch) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH MACULAR (patches in glutes) and PRURITUS (itch). At the time of the report, RASH MACULAR (patches in glutes) and PRURITUS (itch) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant products and treatment medication were reported.
This spontaneous report was received from a pediatric nurse practitioner and a nurse via a company representative and refers to a 14 year old male patient. The patient's concurrent condition, medical history and concomitants medications were not reported. On unknown date 5 to 6 weeks prior to the patient's death (also reported as ''last Wednesday''), the patient was vaccinated with GARDASIL 9 (lot #, expiration date, dose, route and site of administration were not reported) for immunisation (also reported as vaccination). On unknown date, the patient complained of a headache after received GARDASIL 9 but the patient was not seen for this initial headache. On unspecified date, the patient developed a severe headache and went to hospital emergency room, from there he was transferred to the hospital, where he later passed away of acute disseminated encephalomyelitis on unknown date. It was unknown if an autopsy was performed. The causality between the event and GARDASIL 9 was not provided by the reporters. However, an unspecified physician from the hospital reported that, the patient's death was related to the GARDASIL 9. Upon internal review, the event of acute disseminated encephalomyelitis was considered to be medically significant. Reported Cause(s) of Death: Acute Disseminated Encephalomyelitis.